Previous 10 | Next 10 |
London, UK , Aug. 03, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in fireside chats at ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Easily one of the biggest and most painful ironies in our modern society is the rise of mental health issues. According to data from Mental Health America, in 2020, “9.7% of youth in the U.S. have severe major depre...
Mental health care company COMPASS Pathways (NASDAQ:CMPS) has appointed eminent psychiatrist Guy Goodwin as Chief Medical Officer. Goodwin is Emeritus Professor of Psychiatry at The University of Oxford. Commenting on the appointment, Professor Goodwin said, "I have been working with COMPASS ...
COMPASS announces changes to its Executive Team London, UK – 29 July 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it ...
The global obesity issue is bursting at the seams. According to the World Health Organization, obesity has tripled since 1975. More than 1.9 billion adults were overweight, as of 2016, with more than 650 million considered obese. Plus, more than 340 million children were considered overweig...
NetworkNewsWire Editorial Coverage : In July 2012, Congress created what is known as Breakthrough Therapy designation, a distinction that affords biotechnology and pharmaceutical companies an expedited review process for experimental drugs that may have treatment advantages over existing th...
London, UK – 21 July 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has appointed Danielle Schlosser PhD as Senior Vic...
Moha El-Jaw/iStock via Getty Images "Magic mushrooms," LSD, and MDMA, once thought to be purely recreational drugs, are under investigation by many publicly traded companies as potential psychedelic treatments for a range of diseases. An increasing amount of research is demonstrating that the...
ATAI Life Sciences N.V (ATAI), Compass Pathways Plc (CMPS), and Mind Medicine Holdings (MNMD) are 3 stocks that are looking to commercialize psychedelics for medical use. Investors should keep them on their radars as they have massive long-term potential. Norms and regulations in society...
adrian825/iStock via Getty Images Psychedelic drug developers started as buys Citi, Credit Suisse, Canaccord Genuity, and Cantor Fitzgerald have initiated Atai Life Sciences ([[ATAI]] +2.3%) with buy/overweight ratings. Credit Suisse has a $25 price target on shares (~35% upside) Credit...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...